𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Metoclopramide-induced tardive dyskinesia in an infant

✍ Scribed by Nicte I. Mejia; Joseph Jankovic


Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
63 KB
Volume
20
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

We describe a 1‐year‐old girl who developed orofaciolingual stereotypy at age 2 months after a 17‐day treatment with metoclopramide for gastroesophageal reflux. The stereotypy, documented by sequential videos, persisted for at least 9 months after the drug was discontinued. This patient represents the first documented case of tardive dyskinesia in an infant. We also review previous reports of tardive dyskinesia in children. Β© 2004 Movement Disorder Society


πŸ“œ SIMILAR VOLUMES


Levetiracetam in tardive dyskinesia: An
✍ Spiros Konitsiotis; Sofia Pappa; Christos Mantas; Venos Mavreas πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 53 KB πŸ‘ 2 views

Levetiracetam (LEV), a novel antiepileptic drug, has demonstrated antidyskinetic effect in preclinical animal models of Parkinson's disease (PD) and in one open label study in PD patients with levodopa-induced dyskinesia. The acute antidyskinetic effects of LEV in patients with tardive dyskinesia we

The association between risk factors for
✍ S. K. Schultz; V. Ellingrod; F. W. Fleming; N. C. Andreasen πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 61 KB πŸ‘ 1 views

We examined whether an oral challenge dose of the amino acid phenylalanine (a dopamine precursor) exacerbates the abnormal movements of tardive dyskinesia (TD). We also examined age, gender, treatment duration, and baseline movement severity in relation to phenylalanine-induced changes in movements.

Levodopa-induced dyskinesia in an autops
✍ Jong-Min Kim; Ki Hyeong Lee; Yoon-La Choi; Gi Yeong Choe; Beom S. Jeon πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 394 KB πŸ‘ 1 views

## Abstract It is common for patients with idiopathic Parkinson's disease to develop levodopa‐induced dyskinesia. This report provides what we believe is the first videotape presentation of levodopa‐induced dyskinesia in a patient with progressive supranuclear palsy. To our knowledge, there is only